Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Pharmacodynamic analysis of a serine protease inhibitor, MK-4519, against hepatitis C virus using a novel in vitro pharmacodynamic system.

Brown AN, McSharry JJ, Adams JR, Kulawy R, Barnard RJ, Newhard W, Corbin A, Hazuda DJ, Louie A, Drusano GL.

Antimicrob Agents Chemother. 2012 Mar;56(3):1170-81. doi: 10.1128/AAC.05383-11. Epub 2011 Dec 12.

2.

Antiviral pharmacodynamics in hollow fibre bioreactors.

McSharry JJ, Drusano GL.

Antivir Chem Chemother. 2011 May 12;21(5):183-92. doi: 10.3851/IMP1770. Review.

PMID:
21566264
3.

Zanamivir, at 600 milligrams twice daily, inhibits oseltamivir-resistant 2009 pandemic H1N1 influenza virus in an in vitro hollow-fiber infection model system.

Brown AN, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1740-6. doi: 10.1128/AAC.01628-10. Epub 2011 Jan 24.

4.

Effect of half-life on the pharmacodynamic index of zanamivir against influenza virus delineated by a mathematical model.

Brown AN, Bulitta JB, McSharry JJ, Weng Q, Adams JR, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2011 Apr;55(4):1747-53. doi: 10.1128/AAC.01629-10. Epub 2011 Jan 24.

5.

In vitro system for modeling influenza A virus resistance under drug pressure.

Brown AN, McSharry JJ, Weng Q, Driebe EM, Engelthaler DM, Sheff K, Keim PS, Nguyen J, Drusano GL.

Antimicrob Agents Chemother. 2010 Aug;54(8):3442-50. doi: 10.1128/AAC.01385-09. Epub 2010 May 24.

6.

Rapid quantification of single-nucleotide mutations in mixed influenza A viral populations using allele-specific mixture analysis.

Liu CM, Driebe EM, Schupp J, Kelley E, Nguyen JT, McSharry JJ, Weng Q, Engelthaler DM, Keim PS.

J Virol Methods. 2010 Jan;163(1):109-15. doi: 10.1016/j.jviromet.2009.09.007. Epub 2009 Sep 15.

PMID:
19761797
7.

Prediction of the pharmacodynamically linked variable of oseltamivir carboxylate for influenza A virus using an in vitro hollow-fiber infection model system.

McSharry JJ, Weng Q, Brown A, Kulawy R, Drusano GL.

Antimicrob Agents Chemother. 2009 Jun;53(6):2375-81. doi: 10.1128/AAC.00167-09. Epub 2009 Apr 13.

8.

Pharmacodynamics of cidofovir for vaccinia virus infection in an in vitro hollow-fiber infection model system.

McSharry JJ, Deziel MR, Zager K, Weng Q, Drusano GL.

Antimicrob Agents Chemother. 2009 Jan;53(1):129-35. doi: 10.1128/AAC.00708-08. Epub 2008 Oct 13.

9.

Modeling amantadine treatment of influenza A virus in vitro.

Beauchemin CA, McSharry JJ, Drusano GL, Nguyen JT, Went GT, Ribeiro RM, Perelson AS.

J Theor Biol. 2008 Sep 21;254(2):439-51. doi: 10.1016/j.jtbi.2008.05.031. Epub 2008 Jul 23.

10.

Sargassum fusiforme fraction is a potent and specific inhibitor of HIV-1 fusion and reverse transcriptase.

Paskaleva EE, Lin X, Duus K, McSharry JJ, Veille JC, Thornber C, Liu Y, Lee DY, Canki M.

Virol J. 2008 Jan 15;5:8. doi: 10.1186/1743-422X-5-8.

11.

Phenotypic drug susceptibility assay for influenza virus neuraminidase inhibitors.

McSharry JJ, McDonough AC, Olson BA, Drusano GL.

Clin Diagn Lab Immunol. 2004 Jan;11(1):21-8.

12.

Use of a single monoclonal antibody to determine the susceptibilities of herpes simplex virus type 1 and type 2 clinical isolates to acyclovir.

Chutkowski C, Olson B, McDonough A, Mahoney J, McSharry JJ.

Clin Diagn Lab Immunol. 2002 Nov;9(6):1379-81.

13.

Dietary titanium and infant growth.

Schwietert CW, Yaghoubi S, Gerber NC, McSharry JJ, McCue JP.

Biol Trace Elem Res. 2001 Nov;83(2):149-67.

PMID:
11762532
14.

Inhibition of ganciclovir-susceptible and -resistant human cytomegalovirus clinical isolates by the benzimidazole L-riboside 1263W94.

McSharry JJ, McDonough A, Olson B, Talarico C, Davis M, Biron KK.

Clin Diagn Lab Immunol. 2001 Nov;8(6):1279-81.

15.

Susceptibilities of human cytomegalovirus clinical isolates to BAY38-4766, BAY43-9695, and ganciclovir.

McSharry JJ, McDonough A, Olson B, Hallenberger S, Reefschlaeger J, Bender W, Drusano GL.

Antimicrob Agents Chemother. 2001 Oct;45(10):2925-7.

16.

Analysis of virus-infected cells by flow cytometry.

McSharry JJ.

Methods. 2000 Jul;21(3):249-57. Review.

PMID:
10873479
17.

Antiviral drug susceptibility assays: going with the flow.

McSharry JJ.

Antiviral Res. 1999 Aug;43(1):1-21. Review.

PMID:
10480260
18.

Rapid ganciclovir susceptibility assay using flow cytometry for human cytomegalovirus clinical isolates.

McSharry JJ, Lurain NS, Drusano GL, Landay AL, Notka M, O'Gorman MR, Weinberg A, Shapiro HM, Reichelderfer PS, Crumpacker CS.

Antimicrob Agents Chemother. 1998 Sep;42(9):2326-31.

19.

Uses of flow cytometry in virology.

McSharry JJ.

Clin Microbiol Rev. 1994 Oct;7(4):576-604. Review.

20.

Novel oral combination chemotherapy in the treatment of intermediate-grade and high-grade AIDS-related non-Hodgkin's lymphoma.

Remick SC, McSharry JJ, Wolf BC, Blanchard CG, Eastman AY, Wagner H, Portuese E, Wighton T, Powell D, Pearce T, et al.

J Clin Oncol. 1993 Sep;11(9):1691-702.

PMID:
8355036
21.

Metastatic breast cancer in a young patient seropositive for human immunodeficiency virus.

Remick SC, Harper GR, Abdullah MA, McSharry JJ, Ross JS, Ruckdeschel JC.

J Natl Cancer Inst. 1991 Mar 20;83(6):447-8. No abstract available.

PMID:
1999852
22.

Rapid detection of herpes simplex virus in clinical samples by flow cytometry after amplification in tissue culture.

McSharry JJ, Costantino R, McSharry MB, Venezia RA, Lehman JM.

J Clin Microbiol. 1990 Aug;28(8):1864-6.

23.

Detection and quantitation of human immunodeficiency virus-infected peripheral blood mononuclear cells by flow cytometry.

McSharry JJ, Costantino R, Robbiano E, Echols R, Stevens R, Lehman JM.

J Clin Microbiol. 1990 Apr;28(4):724-33.

24.
25.

Sendai virus glycoproteins are T cell-dependent B cell mitogens.

Kizaka S, Goodman-Snitkoff G, McSharry JJ.

Infect Immun. 1983 May;40(2):592-600.

26.

Mitogenic activity of Sindbis virus and its isolated glycoproteins.

Goodman-Snitkoff G, McSharry JJ.

Infect Immun. 1982 Dec;38(3):1242-8.

27.

Isolation of poliovirus variants resistant to and dependent on arildone.

Schrom M, Laffin JA, Evans B, McSharry JJ, Caliguiri LA.

Virology. 1982 Oct 30;122(2):492-7. No abstract available.

PMID:
6293183
28.

Activation of the alternative complement pathway by enveloped viruses containing limited amounts of sialic acid.

McSharry JJ, Pickering RJ, Caliguiri LA.

Virology. 1981 Oct 30;114(2):507-15. No abstract available.

PMID:
6270885
29.

The glycoprotein isolated from vesicular stomatitis virus is mitogenic for mouse B lymphocytes.

Goodman-Snitkoff G, Mannino RJ, McSharry JJ.

J Exp Med. 1981 Jun 1;153(6):1489-502.

30.

Activation of mouse lymphocytes by vesicular stomatitis virus.

Goodman-Snitkoff GW, McSharry JJ.

J Virol. 1980 Sep;35(3):757-65.

31.

Effect of arildone on modifications of poliovirus in vitro.

Caliguiri LA, McSharry JJ, Lawrence GW.

Virology. 1980 Aug;105(1):86-93. No abstract available.

PMID:
6251614
32.

Inhibition of uncoating of poliovirus by arildone, a new antiviral drug.

McSharry JJ, Caliguiri LA, Eggers HJ.

Virology. 1979 Sep;97(2):307-15. No abstract available.

PMID:
224584
33.

Biological properties of the VSV glycoprotein. II. Effects of the host cell and of the glycoprotein carbohydrate composition on hemagglutination.

McSharry JJ, Ledda CA, Freiman HJ, Choppin PW.

Virology. 1978 Jan;84(1):183-8. No abstract available.

PMID:
202076
34.

Biological properties of the VSV glycoprotein. 1. Effects of the isolated glycoprotein on host macromolecular synthesis.

McSharry JJ, Choppin PW.

Virology. 1978 Jan;84(1):172-82. No abstract available.

PMID:
202075
35.
36.

Isolation and characterization of the nonglycosylated membrane protein and a nucleocapsid complex from the paramyxovirus SV5.

McSharry JJ, Compans RW, Lackland H, Choppin PW.

Virology. 1975 Oct;67(2):365-74. No abstract available.

PMID:
1189285
37.
38.

Carbohydrate composition of vesicular stomatitis virus.

McSharry JJ, Wagner RR.

J Virol. 1971 Mar;7(3):412-5.

39.

Lipid composition of purified vesicular stomatitis viruses.

McSharry JJ, Wagner RR.

J Virol. 1971 Jan;7(1):59-70.

Supplemental Content

Loading ...
Support Center